TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card

ORLANDO, Fla., July 28, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or the "Company"), a biopharmaceutical company focused on the development, marketing and distribution of opioid-related immunotherapies, announced today that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with its 2014 Annual Meeting of Shareholders to be held on Thursday, September 4, 2014, at 10 a.m., East Standard Time. The record date for determining those shareholders eligible to receive notice of, and to vote at, the 2014 Annual Meeting was set as of July 15, 2014.

TNI BioTech strongly urges shareholders to vote, either by telephone, Internet or mail. Shareholders may also vote at the meeting, which will take place at the Citrus Club, 255 South Orange Avenue, Suite 1800, Orlando, FL 32801.

Commencing with the 2014 Annual Meeting, all directors standing for election would be elected to serve only until the following year's annual meeting.

All of TNI BioTech's new board nominees will qualify as independent directors under the NASDAQ listing rules. All Board committee memberships are restricted to independent directors.

SUPPORT TNI BIOTECH BY VOTING YOUR PROXY CARD TODAY

Your vote is important, no matter how many shares you own. Whether or not you plan to attend the Annual Meeting, we urge you to protect your investment in TNI BioTech by voting your shares via a toll-free telephone number or over the Internet. If you received a proxy card or voting instruction card by mail, you may submit your proxy card or voting instruction card by completing, signing, dating and mailing your proxy card or voting instruction card in the postage-paid envelope provided.

On behalf of your Board of Directors, we thank you for your continued support. We look forward to reporting our continued progress to you. 

Cautionary Note Regarding Forward-Looking Statements

This document includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the plans, objectives, expectations and intentions of TNIB and other statements that are not historical facts. These statements are based on the current expectations and beliefs of TNIB's management and are subject to uncertainty and changes in circumstances. TNIB cautions readers that any forward-looking information is not a guarantee of future performance and that actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, strategic and/or regulatory factors, as well as other factors affecting the operation of the businesses of TNIB. More detailed information about these factors may be found in filings by TNIB with the SEC, including its most recent Annual Report on Form 10-K in the sections entitled "Caution Concerning Forward-Looking Statements" and "Risk Factors." Various other factors could cause actual results to differ from those set forth in the forward-looking statements, and such results may not be fully realized or may take longer to realize than expected. TNIB is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

About TNI BioTech, Inc.

TNI BioTech, Inc. is a biopharmaceutical company involved in manufacturing, distribution, and marketing of our rights to our immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system in fighting chronic and life threatening diseases. Our goal is to provide affordable sustainable health care in emerging nations where little or no treatments exist for many of these diseases.

Our therapies have been shown in clinical trials to stimulate the immune system in patients with cancer, autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, fibromyalgia, melanoma, prostate cancer, cervical cancer, and inflammatory bowel disease.  The therapies may be used as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery and in combination with antibiotics or retroviral drug therapy in the treatment of a variety of infectious diseases, including patients with HIV/AIDS.

Contact:
Dennis S. Dobson
203-258-0159

SOURCE TNI BioTech, Inc.